待完成后，认购事项所得款项总额及所得款项净额预计将分别约为2215万港元及2202万港元。认购事项 的所得款项净额拟定用途为：约1320万港元用作偿还集团逾期应付租赁款项及其他将于本公布日期起3 个月内到期的未偿还债券应付款项及应付租赁款项;及约880万港元用作集团一般营运资金。 创业集团控股(02221)发布公告，于2025年7月29日，公司拟向认购人(沈定女士、赵素梅女士、黄智俊先 生、张红兵女士)配发及发行合共2.215亿股认购股份，相当于公司经配发及发行认购股份扩大后之已发 行股本的约12.12%。每股认购股份的认购价为0.10港元，较7月29日收市价每股股份0.069港元溢价约 44.93%。 ...

Core Viewpoint - The company plans to issue a total of 221.5 million subscription shares, representing approximately 12.12% of the enlarged issued share capital after the issuance, at a subscription price of HKD 0.10 per share, which is a premium of about 44.93% over the closing price of HKD 0.069 on July 29 [1] Financial Summary - The total amount expected to be raised from the subscription is approximately HKD 22.15 million, with a net amount of about HKD 22.02 million [1] - The net proceeds from the subscription are intended to be used for the repayment of overdue lease payments and other outstanding bond payments due within three months from the announcement date, amounting to approximately HKD 13.2 million, and for general working capital of approximately HKD 8.8 million [1]

Core Viewpoint - The company, Yaoshi Bang (09885), announced the issuance of a total of 560,400 shares due to the exercise of stock options granted under its 2019 share incentive plan from July 8 to July 29 [1] Group 1 - The company plans to issue a total of 1,985,500 consideration shares at a price of HKD 12 per share based on a share purchase agreement dated July 29 [1]

Group 1 - The company, Pioneer Pharmaceuticals (00399), has entered into subscription agreements with two investors, A and B, to issue a total of 90 million shares at a subscription price of HKD 0.312 per share, which represents a discount of approximately 20% compared to the closing price of HKD 0.39 on the date of the agreements [1][2] - The shares subscribed by Investor A will account for approximately 3.00% of the company's existing issued share capital as of the announcement date, while the shares subscribed by Investor B will account for approximately 1.50% [1] - The total gross proceeds from the subscription will be approximately HKD 28.08 million, with a net amount of approximately HKD 27.78 million, intended for general working capital of the group [2] Group 2 - The board of directors believes that the current market conditions present a good opportunity for the company to strengthen its capital base and financial position through the issuance of subscription shares [2] - The issuance of subscription shares is considered an appropriate means to raise additional funds, as the subscription price is lower than the market price, which was reached after fair negotiations with the investors [2]

Group 1 - The company announced agreements with various subscribers to issue a total of 19.34 million shares at a subscription price of approximately HKD 0.04801 per share [1] - The company also entered into agreements to issue convertible bonds amounting to HKD 15 million each to three different subscribers, with a conversion price of HKD 0.04801 per share [2] - The total gross proceeds from the subscription are approximately HKD 2.79 million, with a net amount of approximately HKD 2.52 million, which will be used to repay group debts and provide working capital [2] Group 2 - The board believes that raising funds through the subscription is reasonable given the recent market conditions, and it provides an opportunity to enhance the company's working capital and financial position [2] - The subscription not only offers fundraising opportunities but also expands the company's shareholder base and capital foundation [2]

Core Points - The company, JOINN LABORATORIES (CHINA) CO., LTD., was established on December 26, 2012, and is registered in the Beijing Economic and Technological Development Zone [2] - The company was approved by the China Securities Regulatory Commission (CSRC) to issue H shares on August 4, 2017, and subsequently listed on the Hong Kong Stock Exchange [2][3] - The registered capital of the company is RMB 749.34822 million [2][3] - The company aims to provide a new drug research and development technology platform for domestic and foreign enterprises, accelerating the industrialization of scientific and technological achievements [5] Company Structure - The company is a permanent joint-stock company, with all assets divided into equal shares, and shareholders are liable only to the extent of their subscribed shares [3] - The company has a total of 270,820,329 shares, with 63,035,301.4 million shares held by domestic investors, accounting for approximately 84.12% of the total share capital, and 11,899,520.6 million H shares held by foreign investors, accounting for approximately 15.88% [9] - The company can issue ordinary shares and, with approval, can also issue other types of shares [6][9] Share Issuance and Management - The company issues shares based on principles of openness, fairness, and justice, ensuring that each share of the same type has equal rights [6] - The company can increase its capital through various methods, including public offerings, private placements, and bonus shares [10] - The company has the right to repurchase its shares under specific circumstances, such as reducing registered capital or merging with other companies [11][12] Shareholder Rights - Shareholders have the right to receive dividends, attend and vote at shareholder meetings, supervise the company's operations, and transfer their shares [28] - The company must maintain a shareholder register that includes details of each shareholder and their respective shareholdings [22][25] - Shareholders can request the company to repurchase their shares if they disagree with resolutions made at shareholder meetings [28]

晶澳太阳能科技 股份有限公司 章程（草案） | | 英文全称：JA Solar Technology Co., Ltd. | | --- | --- | | 第4条 第5条 | 公司注册名称：晶澳太阳能科技股份有限公司 公司住所：河北省宁晋县新兴路 号 123 | 邮政编码：055550 （H 股发行并上市后适用） | 第一章 | 总 则 | 2 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 3 | | 第三章 | 股 份 | 3 | | | 第一节 股份发行 | 3 | | 第二节 | 股份增减和回购 | 5 | | 第三节 | 股份转让 | 7 | | 第四章 | 股东和股东大会 | 7 | | 第一节 | 股东 | 8 | | 第二节 | 股东大会的一般规定 | 10 | | 第三节 | 股东大会的召集 | 15 | | | 第四节 股东大会的提案与通知 | 16 | | 第五节 | 股东大会的召开 | 17 | | 第六节 | 股东大会的表决和决议 | 20 | | 第五章 | 董事会 | 23 | | 第一节 | 董事 | 23 | | 第二节 | 独立董事 | 2 ...

第四条 公司注册名称：杭州中威电子股份有限公司。 英文全称：Joyware Electronics Co.,Ltd | 第一章 | 总 | 则 2 | | --- | --- | --- | | 第二章 | | 经营宗旨和范围 3 | | 第三章 | 股 | 份 3 | | 第一节 | | 股份发行 3 | | 第二节 | | 股份增减和回购 4 | | 第三节 | | 股份转让 5 | | 第四章 | | 股东和股东大会 6 | | 第一节 | | 股 东 6 | | 第二节 | | 股东大会的一般规定 8 | | 第三节 | | 股东大会的召集 10 | | 第四节 | | 股东大会的提案与通知 12 | | 第五节 | | 股东大会的召开 13 | | 第六节 | | 股东大会的表决和决议 16 | | 第五章 | | 董事会 20 | | 第一节 | | 董 事 20 | | 第二节 | | 董事会 23 | | 第六章 | | 总经理及其他高级管理人员 29 | | 第七章 | | 监事会 31 | | 第一节 | | 监事 31 | | 第二节 | | 监事会 31 | | 第八章 | | 财务会 ...